Comparative Pharmacology
Head-to-head clinical analysis: BRONCHITOL versus CYSTEINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRONCHITOL versus CYSTEINE HYDROCHLORIDE.
BRONCHITOL vs CYSTEINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases mucociliary clearance by reducing mucus viscosity and facilitating cough; may also stimulate surfactant production and have anti-inflammatory effects.
Cysteine hydrochloride serves as a precursor to glutathione, an important antioxidant. It also provides a source of cysteine for protein synthesis and acts as a mucolytic agent by reducing disulfide bonds in mucus glycoproteins, thereby decreasing viscosity.
400 mg (2 capsules) inhaled twice daily via a dry powder inhaler.
Intravenous: 0.8-1 g/m²/day divided every 6 hours for acetaminophen poisoning; for parenteral nutrition, 0.66-1.7 g of cysteine/kg/day (as hydrochloride).
None Documented
None Documented
Terminal elimination half-life is approximately 1.6 hours, indicating rapid clearance from plasma; however, the residence time in airways is prolonged due to mucoadhesion.
Terminal elimination half-life: 1.5-3 hours in adults with normal renal function; prolonged in renal impairment (up to 8-10 hours in severe cases).
Primarily renal excretion of unchanged drug; approximately 80-90% of the inhaled dose is recovered in urine within 24 hours, with less than 5% in feces.
Renal: 40-60% as unchanged drug and metabolites; fecal: <5%; minor biliary elimination; route of administration (e.g., intravenous) influences exact percentages.
Category C
Category C
Mucolytic
Mucolytic